CagriSema REIMAGINE 5: A Lower-Dose Combination Meets Tirzepatide Head to Head

The 60-week Phase 3 REIMAGINE 5 clinical trial provides the first direct head-to-head comparison between CagriSema and the dual GIP/GLP-1 receptor agonist tirzepatide. By evaluating an intermediate, lower-dose tier of CagriSema (1.0 mg cagrilintide / 1.0 mg semaglutide) against low-dose tirzepatide (5 mg) in adults with type 2 diabetes, these data establish how dual amylin/GLP-1 receptor co-targeting compares to dual incretin receptor agonism within the same randomized setting.

What Is the Compound? Dual Amylin/GLP-1 vs. Dual Incretin Pharmacology

CagriSema is an investigational, fixed-dose subcutaneous co-formulation developed by Novo Nordisk, combining two distinct neuroendocrine peptide analogues into a single once-weekly autoinjector: the selective amylin analogue cagrilintide and the established GLP-1 receptor agonist semaglutide. While REIMAGINE 2 and REDEFINE 1 evaluated the maximum manufactured dose (2.4 mg cagrilintide / 2.4 mg semaglutide), REIMAGINE 5 focused on an intermediate maintenance tier: 1.0 mg cagrilintide / 1.0 mg semaglutide (1/1 mg).

The scientific debate between CagriSema and tirzepatide highlights two distinct multi-target pharmacological mechanisms:

• Dual Amylin and GLP-1 Receptor Agonism (CagriSema): Combines incretin-driven insulinotropic and hypothalamic satiety action (semaglutide) with calcitonin receptor core complex (AMY1–3) activation in the area postrema and nucleus of the solitary tract (NTS) in the hindbrain (cagrilintide). This pairs gastric delay with physiological postprandial fullness and mealtime glucagon suppression.
• Dual Incretin GIP and GLP-1 Receptor Agonism (Tirzepatide): Combines GLP-1 receptor activation with glucose-dependent insulinotropic polypeptide receptor (GIPR) signaling. GIP agonism enhances insulin sensitivity, buffers postprandial lipid handling in subcutaneous white adipose tissue, and acts alongside GLP-1 on central hypothalamic satiety circuits.
• Formulated Precision: CagriSema is a precision co-crystallization engineered for liquid stability and synchronized absorption. Its clinical trial findings cannot be replicated by compounding independent peptides or manually mixing separate research solutions.

By comparing intermediate doses of both multi-pathway agents within the same trial, REIMAGINE 5 directly examines how hindbrain/hypothalamic neuroendocrine co-targeting compares to dual incretin receptor co-agonism.

How the Study Worked: REIMAGINE 5 Head-to-Head Trial Architecture

The REIMAGINE 5 trial was designed as a prospective, randomized, open-label with blinded-endpoint, active-comparator Phase 3 study to evaluate glycemic noninferiority and relative weight-loss efficacy between two competing multi-target therapies:

Complete clinical protocol parameters and primary corporate releases are documented in the Novo Nordisk Primary Corporate Announcement.

Results and Key Findings: Glycemic Noninferiority with Superior Weight Loss

The 60-week topline data from REIMAGINE 5 demonstrated that lower-dose CagriSema 1/1 mg achieves glycemic control comparable to tirzepatide 5 mg while delivering a greater reduction in total body weight:

• Primary Glycemic Noninferiority Met: Under the on-treatment efficacy estimand, CagriSema 1/1 mg produced a mean HbA1c reduction of 1.71 percentage points, compared to 1.67 percentage points with tirzepatide 5 mg. The estimated treatment difference (-0.04% points) successfully met the prespecified statistical noninferiority margin, confirming equivalent glycemic potency at these dose tiers.
• Statistically Superior Weight Loss (-12.4% vs. -9.1%): Patients receiving CagriSema 1/1 mg achieved a mean body weight loss of 12.4%, statistically superior to the 9.1% mean weight loss achieved with tirzepatide 5 mg (an estimated treatment difference of -3.3%, p < 0.05).
• Dose-Specific Boundaries: These results reflect a specific comparison between CagriSema 1/1 mg and tirzepatide 5 mg. They do not demonstrate superiority over maximum-dose tirzepatide (10 mg or 15 mg), which routinely yields higher weight-loss percentages in registrational SURPASS trials.
• Topline Announcement Scope: These findings represent primary topline data released by the sponsor. Full peer-reviewed publication tables will provide categorical responder rates (≥5%, ≥10%, and ≥15% weight loss) and exact HbA1c <7.0% target achievement percentages.

The Study in Plain English: Understanding Head-to-Head Trial Metrics

Interpreting active-comparator clinical trials requires understanding the distinction between noninferiority margins and comparative superiority:

Key Insights: What Makes the REIMAGINE 5 Readout Critical?

The clinical contribution of REIMAGINE 5 provides vital insights for endocrinologists and researchers navigating the competitive landscape of multi-pathway peptides:

• Rigorous Direct Comparisons Over Marketing Claims: Pharmaceutical discussions often assemble cross-trial league tables comparing disparate studies with different baseline populations, placebo responses, and trial durations. REIMAGINE 5 provides randomized, direct evidence comparing dual amylin/GLP-1 signaling against dual GIP/GLP-1 signaling in a shared clinical environment.
• Competitive Potency at Lower Maintenance Doses: Delivering a 1.71% HbA1c reduction and 12.4% weight loss on a 1/1 mg dose demonstrates that CagriSema does not require maximum-strength escalation (2.4/2.4 mg) to compete with established dual incretins in type 2 diabetes.
• Avoiding Over-Generalization: While CagriSema 1/1 mg outperformed tirzepatide 5 mg in weight loss, tirzepatide 5 mg is the lowest therapeutic maintenance dose in the SURPASS program. Higher tirzepatide doses (10 mg and 15 mg) produce significantly greater weight loss (~13% to 15% in type 2 diabetes), underscoring that this readout confirms lower-tier potency rather than class-wide dominance.

Tolerability & The Complete Safety Profile

While the initial corporate announcement confirmed that REIMAGINE 5 met its primary endpoints with an acceptable safety profile, full numerical evaluation requires forthcoming peer-reviewed publications:

• Class-Consistent Gastrointestinal Profile: Gastrointestinal adverse events (mild-to-moderate nausea, vomiting, and diarrhea) occurred across active arms, reflecting the biological overlap between GLP-1, GIP, and amylin receptor pathways.
• Adverse-Event Discontinuation: Detailed publication tables will clarify exact discontinuation rates between CagriSema 1/1 mg and tirzepatide 5 mg, establishing whether dual amylin/GLP-1 co-targeting offers a tolerability advantage over dual incretins at intermediate maintenance tiers.
• Absence of Unexpected Systemic Safety Signals: The sponsor reported no new unexpected organ toxicities, severe hypoglycemia clusters, or cardiovascular liabilities beyond the established profiles of the incretin and amylin drug classes.

For complete trial documentation and primary disclosures, reference the Novo Nordisk Primary Corporate Release.

Comparative Research Themes & Next-Generation Metabolic Pipelines

To contextualize CagriSema within the broader landscape of diabetes and obesity therapeutics, researchers compare multi-receptor mechanisms across active-comparator trials:

For a detailed analysis of comparative amylin biology, explore our guide: Eloralintide vs Cagrilintide: Amylin Agonists Compared. To review lower-dose obesity data with CagriSema, read: CagriSema REDEFINE 9 Results: Lower-Dose Phase 3 Trial Data.

What Patients and Clinicians Can Look Forward To

CagriSema remains an investigational combination therapy undergoing active global Phase 3 evaluation; it is not yet approved by the U.S. FDA or international health authorities. However, the successful completion of REIMAGINE 5 provides the first direct evidence demonstrating that an amylin/GLP-1 combination can compete against dual incretin therapy in type 2 diabetes.

For clinicians and patients, these findings highlight the expanding therapeutic menu in metabolic disease. Future clinical practice will not be confined to selecting between GLP-1 monotherapy and GIP/GLP-1 co-agonism; dual amylin/GLP-1 co-formulations emerge as a potent alternative that delivers equivalent glycemic control and competitive weight loss at intermediate dose tiers.

Questions for the Next Stage of Research

While the 60-week REIMAGINE 5 findings establish clear proof-of-concept, several vital clinical questions guide ongoing evaluation:

• High-Dose Comparative Trials: How will maximum-dose CagriSema (2.4/2.4 mg) compare directly against maximum-dose tirzepatide (15 mg) in dedicated randomized head-to-head trials in type 2 diabetes?
• Long-Term Cardiovascular Outcomes: Will co-formulating cagrilintide with semaglutide preserve or amplify the proven major adverse cardiovascular event (MACE) and nephroprotective benefits established by semaglutide monotherapy?
• Comparative Discontinuation Dynamics: Once detailed peer-reviewed safety tables are published, how will real-world treatment persistence and gastrointestinal adverse-event profiles compare between CagriSema and tirzepatide?

Explore Our Research Tools

To assist laboratory scientists and clinicians in tracking peptide calculations, experimental schedules, and analytical observations, explore our specialized software suite:

• Calculate volume measurements and concentration parameters with the interactive Peptide Calculator.
• Structure research intervals, timing windows, and observation phases inside the Protocol Builder.
• Log laboratory markers, baseline patient metrics, and analytical notes with the Protocol Tracker Tool.

Scientific References & Primary Trial Documents

• Novo Nordisk: Phase 3 REIMAGINE 5 Head-to-Head Trial of CagriSema vs Tirzepatide in Type 2 Diabetes Successfully Completed (Primary Topline Announcement)
• CagriSema REDEFINE 9 Results: Lower-Dose Phase 3 Trial Data
• CagriSema REIMAGINE 2 Results: Phase 3 Trial Data
• Eloralintide vs Cagrilintide: Amylin Agonists Compared